Japanese journal of clinical oncology · 2026
Trends in net survival for cancers of the liver and pancreas in Japan, 2000-14 (CONCORD-3).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nishio Marisa, Matz Melissa, Sugiyama Hiromi, Oki Izumi, Shibata Akiko, Nakata Kayo, Kajiwara Saito Mari, Matsuzaka Masashi, Oze Isao, Watanabe Kaname, Tanaka Rina, Gatellier Laureline, Yoshida Isao, Ito Hidemi, Teramoto Norihiro, Yamashita Natsumi, Kaizaki Yasuharu, Moki Fumitaka, Kurosawa Katsuki, Nemoto Yuji, Narimatsu Hiroto, Kanemura Seiki, Miyashiro Isao, Mori Daisuke, Fujita Shin, Matsuda Tomohiro, Coleman Michel P, Allemani Claudia, Di Carlo Veronica
Аннотация
BACKGROUND: Pancreatic and liver cancers are the 6th and 7th most common cancers in Japan and are major contributors to cancer mortality.
METHODS: We used CONCORD-3 data to estimate survival for primary pancreas and liver cancers, registered in 16 population-based regional cancer registries. Five-year net survival was estimated with the Pohar Perme estimator for three periods (2000-2004, 2005-2009, 2010-2014), adjusted for age using International Cancer Survival Standard weights.
RESULTS: We analysed data on 79 636 patients with pancreatic cancer and 122 792 patients with liver cancer. Carcinoma accounted for 91.4% of pancreatic cancers, and age-standardized 5-year net survival remained poor, from 6.4% (95% CI: 5.9%-6.9%) in 2000-2004 to 8.3% (7.8%-8.7%) in 2010-2014. Five-year net survival for localized disease increased slightly, from 39.3% (33.4%-45.2%) in 2000-2004 to 44.2% (36.8%-51.7%) in 2010-2014. Distant-stage pancreatic cancer survival remained <2% throughout 2000-2014. Hepatocellular carcinoma accounted for 83.7% of liver cancers. Five-year net survival increased from 27.4% (26.8%-28.1%) in 2000-2004 to 33.4% (32.7%-34.0%) in 2010-2014. Five-year net survival for localized liver cancer increased from 38.0% (35.3%-40.7%) in 2000-2004 to 48.8% (46.4%-51.3%) in 2010-2014, while distant-stage survival remained <5% throughout 2000-2014.
CONCLUSIONS: Five-year net survival remained poor for patients with pancreatic cancer in Japan throughout 2000-2014. Survival for liver cancer improved slightly. Early detection and improved diagnostic methods may help in reduce the proportion of patients diagnosed with advanced-stage.
METHODS: We used CONCORD-3 data to estimate survival for primary pancreas and liver cancers, registered in 16 population-based regional cancer registries. Five-year net survival was estimated with the Pohar Perme estimator for three periods (2000-2004, 2005-2009, 2010-2014), adjusted for age using International Cancer Survival Standard weights.
RESULTS: We analysed data on 79 636 patients with pancreatic cancer and 122 792 patients with liver cancer. Carcinoma accounted for 91.4% of pancreatic cancers, and age-standardized 5-year net survival remained poor, from 6.4% (95% CI: 5.9%-6.9%) in 2000-2004 to 8.3% (7.8%-8.7%) in 2010-2014. Five-year net survival for localized disease increased slightly, from 39.3% (33.4%-45.2%) in 2000-2004 to 44.2% (36.8%-51.7%) in 2010-2014. Distant-stage pancreatic cancer survival remained <2% throughout 2000-2014. Hepatocellular carcinoma accounted for 83.7% of liver cancers. Five-year net survival increased from 27.4% (26.8%-28.1%) in 2000-2004 to 33.4% (32.7%-34.0%) in 2010-2014. Five-year net survival for localized liver cancer increased from 38.0% (35.3%-40.7%) in 2000-2004 to 48.8% (46.4%-51.3%) in 2010-2014, while distant-stage survival remained <5% throughout 2000-2014.
CONCLUSIONS: Five-year net survival remained poor for patients with pancreatic cancer in Japan throughout 2000-2014. Survival for liver cancer improved slightly. Early detection and improved diagnostic methods may help in reduce the proportion of patients diagnosed with advanced-stage.